| Autor: |
Gul MH, Siddiqui AR, Zehra F, Rehmani M, Waheed F, Masood N, Saqib M, Keen M, Keshetty SS, Maqsood M, Atwal SA, Sikandari MH, Wardak AB |
| Jazyk: |
angličtina |
| Zdroj: |
Oncology (Williston Park, N.Y.) [Oncology (Williston Park)] 2024 Aug 19; Vol. 38 (8), pp. 311-314. |
| DOI: |
10.46883/2024.25921025 |
| Abstrakt: |
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the accumulation of malignant myeloid progenitor hematopoietic cells in the bone marrow and peripheral blood. Recent studies have shown promising results with the use of small molecule inhibitors and targeted therapy in the treatment of patients with AML. One such molecule is venetoclax, which has been approved in AML by the FDA in combination with hypomethylating agents or low-dose cytarabine. We thoroughly searched electronic literature related to venetoclax and its role in AML, using databases such as MEDLINE, PubMed, Google Scholar, and PsychInfo, through April 2024. We applied population, intervention, comparison, and outcome criteria, specifically focusing on studies with a population using venetoclax from review articles and clinical trials. All selected studies were required to be in English, and any study that did not involve the use of venetoclax was excluded. A meticulous literature review was conducted to consolidate the current knowledge and new combination therapies on AML. In our review article, we focused on the latest advances in the treatment of patients with AML. Based on the literature, we recommend that physicians prioritize the use of venetoclax in the management of this deadly disease because it has been shown to significantly impact the course of the disease. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
